FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment – Drug Information Update

November 30, 2021
12:00AM - 12:00AM

All Times Eastern

Tuesday, November 30, 2021

Join the Meeting

The U.S. Food and Drug Administration (FDA) is announcing an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss Merck and Ridgeback’s request for an emergency use authorization (EUA) for molnupiravir, an investigational antiviral drug to treat COVID-19. On Nov. 30, the advisory committee will meet to discuss the available data supporting the use of molnupiravir to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who have tested positive for COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The FDA will also present its perspective regarding the sponsor’s data. There will be an open public hearing during which the public will be given an opportunity to provide comments. The FDA intends to live stream the AMDAC meeting on the agency’s YouTube page. The meeting will also be webcast from the FDA website.

Learn more.